, Volume 78, Issue 7, pp 747–758 | Cite as

Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers

  • Lesley J. Scott
Adis Drug Evaluation


Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. This article summarizes the pharmacological properties of apatinib and reviews its clinical use in chemotherapy-experienced patients with advanced gastric adenocarcinoma, including gastroesophageal adenocarcinoma (GEA), or with other advanced cancers such as non-small cell lung cancer (NSCLC), breast cancer, gynaecological cancers, hepatocellular carcinoma (HCC), thyroid cancer and sarcomas. As third- or subsequent-line therapy, oral apatinib significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with placebo and had a manageable safety profile in Chinese patients with advanced or metastatic gastric cancer or GEA participating in randomized, double-blind, multicentre, phase 2 and 3 trials. More limited evidence also supports it use as subsequent-line treatment in Chinese patients with other advanced or metastatic solid tumours, including NSCLC, breast cancer and HCC. Further clinical experience and long-term pharmacovigilance data are required to more definitively establish the efficacy and safety profile of apatinib, including its use in combination with other chemotherapy agents and its role in the management of other types of advanced or metastatic solid tumours. In the meantime, given its convenient administration regimen and the limited treatment options and poor prognosis for patients with advanced or metastatic solid tumours, apatinib is an important, emerging treatment option for adult patients with advanced gastric adenocarcinoma or GEA who have progressed or relapsed after chemotherapy.



During the peer review process, the manufacturer of apatinib was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Sun H, Zhu M-S, Wu W-R, et al. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: the jury is still out. World J Hepatol. 2014;6(12):830–5.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Nair M, Sandhu SS, Sharma AK. Cancer molecular markers: a guide to cancer detection and management. Semin Cancer Biol. 2018. Scholar
  3. 3.
    Amanam I, Chung V. Targeted therapies for pancreatic cancer. Cancers. 2018. Scholar
  4. 4.
    Geng R, Li J. Apatinib for the treatment of gastric cancer. Expert Opin Pharmacother. 2015;16(1):117–22.CrossRefPubMedGoogle Scholar
  5. 5.
    Lee A, Djamgoz MBA. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110–22.CrossRefPubMedGoogle Scholar
  6. 6.
    Pinto MP, Owen GI, Retamal I, et al. Angiogenesis inhibitors in early development for gastric cancer. Expert Opin Investig Drugs. 2017;26(9):1007–17.CrossRefPubMedGoogle Scholar
  7. 7.
    Siemann DW, Chaplin DJ, Horsman MR. Realizing the potential of vascular targeted therapy: the rationale for combining vascular disrupting agents and anti-angiogenic agents to treat cancer. Cancer Invest. 2017;35(8):519–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Karasic TB, Rosen MA, O’Dwyer PJ. Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective? Cancer Chemother Pharmacol. 2017;80:661–71.CrossRefPubMedGoogle Scholar
  9. 9.
    Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic efficacy. Clin Cancer Res. 2006;12(17):5018–22.CrossRefPubMedGoogle Scholar
  10. 10.
    Ilson DH, van Hillegersberg R. Management of patients with adneocarcinoma or squamous cancer of the esophagus. Gastroenterology. 2018;154(2):437–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Aoyama T, Yoshikawa T. Apatinib: new third-line option for refractory gastric or GEJ cancer. Nat Rev Clin Oncol. 2016;13(5):268–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Lin C, Wand S, Xie W, et al. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway. Oncotarget. 2016;7(37):59236–44.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Peng H, Zhang Q, Li J, et al. Apatinib inhibits VEGF signalling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget. 2016;7(13):17220–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Peng Q-A, Han Y-W, Zhang Y-L, et al. Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma. Oncotarget. 2017;8(32):52803–22.Google Scholar
  16. 16.
    Li F, Zhu T, Cao B, et al. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Eur J Cancer. 2017;84:184–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Tong XZ, Wang F, Liang S, et al. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol. 2012;83(5):586–97.CrossRefPubMedGoogle Scholar
  18. 18.
    Mi Y-J, Liang Y-J, Huang H-B, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010;70(20):7981–91.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Yu M, Gao Z, Dai X, et al. Population pharmacokinetic and covariate analysis of apatinib, an oral tyrosine kinase inhibitor, in healthy volunteers and patients with solid tumors. Clin Pharmacokinet. 2017;56(1):65–76.CrossRefPubMedGoogle Scholar
  20. 20.
    Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010;10(529):1–8.Google Scholar
  21. 21.
    Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658–67.CrossRefPubMedGoogle Scholar
  22. 22.
    Ding J, Chen X, Gao Z, et al. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos. 2013;41(6):1195–210.CrossRefPubMedGoogle Scholar
  23. 23.
    Liu X, Zhang Y, Chen Q, et al. Pharmacokinetic drug interactions of apatinib with rifampin and itraconazole. J Clin Pharmacol. 2018;58(3):347–56.CrossRefGoogle Scholar
  24. 24.
    Yu W, He JH, Huang M, et al. Phase II study of apatinib in patients with advanced esophageal squamous cell carcinoma after failure of prior radiation and/or chemotherapy [abstract no. 119]. In: 14th World Conference of the Organization for Specialized Studies on the diseases of the Esophagus. 2017.Google Scholar
  25. 25.
    Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31(26):3219–25.CrossRefPubMedGoogle Scholar
  26. 26.
    Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–54.CrossRefPubMedGoogle Scholar
  27. 27.
    Huang L, Wei Y, Shen S, et al. Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients. Oncotarget. 2017;8(17):29346–54.PubMedGoogle Scholar
  28. 28.
    Liu L, Yu H, Huang L, et al. Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer. OncoTargets Ther. 2015;8:921–8.CrossRefGoogle Scholar
  29. 29.
    Liu X, Qin S, Wang Z, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10(153):1–9.Google Scholar
  30. 30.
    Feng J, Shen B, He Z, et al. Real world data about clinical efficacy and safety of apatinib in the treatment of advanced gastric cancer [abstract no. 695P]. Ann Oncol. 2017;28(Suppl 5).Google Scholar
  31. 31.
    Bai C, Zhang R, Ren X, et al. Prospective, multicenter, non-interventional and registry clinical study of apatinib in patients with advanced gastric cancer [abstract no. 137]. J Clin Oncol. 2018;36(4 Suppl).Google Scholar
  32. 32.
    Zhu H, Sun X, Zhou Q, et al. Clinical study of apatinib combined chemotherapy in the treatment of advanced gastric cancer [Chinese]. Chin J Clinl Oncol. 2016;8(6):394–6.Google Scholar
  33. 33.
    Li J, Wang L. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma. Onco Targets Ther. 2017;10:3965–9.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Wang B, Song LJ, Niu PY, et al. Clinical efficacy of apatinib in treatment of advanced gastric cancer [Chinese]. World Chin J Digestol. 2016;24(5):759–64.CrossRefGoogle Scholar
  35. 35.
    Wenying D, Qin S, Li J, et al. Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma or gastroesophageal junction in third- and later-line setting: 500 mg or 850 mg? [abstract no. 35]. J Clin Oncol. 2018;36(4 Suppl).Google Scholar
  36. 36.
    Zhang L, Shi M, Huang C, et al. A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens [abstract no. 7548]. J Clin Oncol. 2012;30(15 Suppl).Google Scholar
  37. 37.
    Wu FY, Zhang SJ, Ren SX, et al. Safety and efficacy of apatinib in patients with previously heavily treated advanced non-squamous non-small-cell lung cancer [abstract no. P3.02c-025]. J Thorac Oncol. 2017;12(1 Suppl.):S1286–7.CrossRefGoogle Scholar
  38. 38.
    Wang SY, Liu Z, Ou W, et al. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy [abstract no. e20626]. J Clin Oncol. 2017;35(15 Suppl).Google Scholar
  39. 39.
    Xu J, Liu X, Yang S, et al. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. Asia Pac J Clin Oncol. 2017. Scholar
  40. 40.
    Song Z, Yu X, Lou G, et al. Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Ther. 2017;10:1821–5.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Ying C, Wu Y. The addition of apatinib to gefitinib or icotinib for advanced non-small cell lung cancer with acquired resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitor: an assessment of effectiveness and safety [abstract no. 1351P]. Ann Oncol. 2017;28(Suppl 5):483.Google Scholar
  42. 42.
    Shi Q, Guo X, Wang Z, et al. The efficacy and safety of apatinib plus S-1 as second-line or laterline chemotherapy for advanced squamous cell lung carcinoma [abstract no. P2.01-011]. J Thorac Oncol. 2017;12(11 Suppl 2):S2073.CrossRefGoogle Scholar
  43. 43.
    Hong W, Li H, Jin X, et al. Apatinib for chemotherapy-refractory extensive stage SCLC: results from a single-center retrospective study [abstract no. P1.07-053]. J Thorac Oncol. 2017;12(1 Suppl):S729.CrossRefGoogle Scholar
  44. 44.
    Hu X, Cao J, Hu W, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14(820):1–8.Google Scholar
  45. 45.
    Hu X, Zhang J, Xu B, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135(8):1961–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Lin Y, Wu Z, Zhang J, et al. Apatinib for metastatic breast cancer in non-clinical trial setting: satisfying efficacy regardless of previous anti-angiogenic treatment. Tumour Biol. 2017;39(6):1–9.CrossRefGoogle Scholar
  47. 47.
    Zhu A, Yuan P, Wang J, et al. A real-world retrospective study of apatinib plus chemotherapy in metastatic breast cancer [abstract no. e12507]. J Clin Oncol. 2017;35(15 Suppl).Google Scholar
  48. 48.
    Fan M, Zhang J, Wang Z, et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat. 2014;143(1):141–51.CrossRefPubMedGoogle Scholar
  49. 49.
    Miao M, Deng G, Luo S, et al. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecol Oncol. 2018;148:286–90.CrossRefPubMedGoogle Scholar
  50. 50.
    Zhang X, Lin Y. 500 mg versus 750 mg daily, pilot dose comparison of apatinib in Chinese patients with progressive radioiodine refractory differentiated thyroid cancer: initial experience of efficacy and safety [abstract no. 427]. Thyroid. 2017;27(Suppl 1):A148.Google Scholar
  51. 51.
    Lin Y, Wang C, Gao W, et al. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget. 2017;8(26):42252–61.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Xie C, Su M, Jin X. Apatinib as a salvage treatment in gynecologic cancer patients failed from two or more lines of prior chemotherapy [abstract no. e17009]. J Clin Oncol. 2017;35(15 Suppl).Google Scholar
  53. 53.
    Li L, Xiao S, Young KH, et al. Efficacy and safety of novel targeted drug apatinib in relapse and refractory non-Hodgkin lymphoma: an open-label, single-armed, exploratory study [abstract]. In: ASH 2017.Google Scholar
  54. 54.
    Kong Y, Sun L, Hou Z, et al. Apatanib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget. 2017;8(62):105596–605.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Li F, Liao Z, Zhao J, et al. Efficacy and safety of apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget. 2017;8(38):64471–80.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Yang W, Zhu B, Li J, et al. Response of advanced soft tissue sarcoma to apatinib: a retrospective analysis [abstract no. e22502]. J Clin Oncol. 2017;35(15 Suppl).Google Scholar
  57. 57.
    Zhu B, Li J, Xie Q, et al. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol Ther. 2018;19(3):198–204.CrossRefPubMedGoogle Scholar
  58. 58.
    Yu W, Yu X, Wu S, et al. Apatinib for patients with unresectable high-grade osteosarcoma progressing after standard chemotherapy: a multi-center retrospective study [abstract no. 11031]. J Clin Oncol. 2017;35(15 Suppl.).Google Scholar
  59. 59.
    Zhou Y, Tang F, Min L, et al. A preliminary study of apatinib in Chinese patients with osteosarcoma [abstract no. e22500]. J Clin Oncol. 2017;35(15 Suppl.).Google Scholar
  60. 60.
    Qin S. Apatinib in Chinese patients with advanced hepatocellular carcinoma: a phase II randomized, open-label trial [abstract no. 4019]. J Clin Oncol. 2014;32(15 Suppl).Google Scholar
  61. 61.
    Yu W-C, Zhnag K-Z, Chen S-G, et al. Efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: a prospective observation study. Medicine. 2018;97(3):e9704.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Jiangsu Hengrui Pharmaceutical Co. Ltd. AiTan (apatinib mesylate tablets): product information sheet. 2014. Accessed 23 Jan 2018.
  63. 63.
    LSK BioPharma. LSK BioPharma’s apatinib receives orphan drug designation in the European Union [media release]. 2017. Accessed 22 Jan 2018.
  64. 64.
    LSK BioPharma. The US FDA grants apatinib orphan drug designation for treatment of gastric cancer [media release]. 2017. Accessed 23 Jan 2018.
  65. 65.
    World Health Organization. Cancer: fact sheet. 2018. Accessed 22 Feb 2018.
  66. 66.
    Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v38–49.CrossRefPubMedGoogle Scholar
  67. 67.
    Ajani JA, D’Amico TA, Almhana K, et al. NCCN gastric cancer version 3.2016: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(10):1286–312.CrossRefPubMedGoogle Scholar
  68. 68.
    Bajaj G, Gupta M, Wang H-WG, et al. Challenges and opportunities with oncology drug development in China. Clin Pharmacol Ther. 2018. Scholar
  69. 69.
    Chen W, Zheng R, Baade PD, et al. Cancer statistics in China. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMedGoogle Scholar
  70. 70.
    Lee HJ, Moon JY, Baek SW. Is treatment-emergent toxicity a biomarker of efficacy of apatinib in gastric cancer? J Clin Oncol. 2016;34(31):3823.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Bai Y, Xu Y, Wu B. Cost-effectiveness and budget impact analysis of apatinib for advanced metastatic gastric cancer from the perspective of the health insurance system. Gastroenterol Res Pract. 2017;2017:2816737.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Chen HD, Zhou J, Wen F, et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol. 2017;143(2):361–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018
corrected publication May 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations